SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...
- Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in ...
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Sutro Biopharma (NASDAQ:STRO) in the last three months. The following table summarizes their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results